| Date |
Subject |
Media |
| 2025-08-12 |
Bora Pharmaceuticals’ Q2 Gross Margin Expected to Outperform Q1; Dual Growth Engines to Boost Second-Half Performance
|
Bora Pharmaceuticals reported second-quarter revenue of NT$5.18 billion, slightly below market expectations, mainly due to the appreciation of the New Taiwan dollar and production delays at its sterile injectable plant in Maryland, USA. With the shutdown impact from the first quarter now resolved, the company’s Q2 gross margin is expected to surpass that of Q1. Looking ahead to the second half of the year, the market expansion of the pediatric epilepsy oral solution VIGAFYDE and increasing CDMO orders—totaling US$138 million in new orders during the first half—are anticipated to steadily boost performance. Analysts are optimistic that these dual engines will drive a significant rebound in gross and operating margins in the latter half of the year. |
| 2025-08-12 |
Orient Europharma Group Maintains Steady Growth, Eyes Drug License Acquisitions and M&A in Southeast Asia to Accelerate Expansion
|
Orient Europharma Group is advancing its dual-track strategy, and General Manager Calvin Tsai stated that the company will continue launching new products to expand its reach across all age demographics while actively expanding into Southeast Asian markets. In the future, the company plans to partner with Orient Pharma to enter markets such as the United States and even the Middle East. This year’s revenue is expected to achieve single-digit growth. With ample cash from asset disposals, the company will continue seeking suitable targets to enrich its product portfolio. In addition to equity-based partnerships, it does not rule out acquiring drug licenses or companies to accelerate its Southeast Asia expansion. |
| 2025-08-12 |
ACRO Biomedical Signs Licensing Agreement with Vietnam’s CT Group to Market Regenerative Eye Implant Across ASEAN
|
ACRO Biomedical has officially signed a licensing agreement with Vietnam’s CT Group to market its regenerative corneal implant—the “Apis Cor Collagen Corneal Matrix”—across ASEAN countries. The product has already received medical device certification from Taiwan’s Ministry of Health and Welfare and has been gaining momentum internationally. Following a prior agreement with Australia’s Oculus Biomed Pty Ltd (OBM) to conduct clinical trials, obtain regulatory approval, and commercialize the product, this new partnership with CT Group not only boosts ACRO Biomedical’s revenue but also showcases Taiwan’s regenerative medicine capabilities while offering new hope to patients in Southeast Asia. |
| 2025-08-12 |
Exclusive Interview with Mobisnet Technology: MIT Medical Robots Target the Smart Care Market
|
Entering the era of smart healthcare, what kind of enterprise can truly deliver flexible, clinically relevant solutions to medical institutions? The answer might surprise you — a software company originally focused on developing government tax systems. |
| 2025-08-12 |
Phison’s aiDAPTIV+ Enters Medical Field in Partnership with Hsinchu MacKay Memorial Hospital
|
Phison Electronics and Hsinchu MacKay Memorial Hospital held a press conference on the 28th to unveil the results of their collaboration, officially launching an on-premise generative AI system. This marks the hospital as one of the first medical institutions in Taiwan to deploy and operate a large language model (LLM) trained and inferenced entirely in-house. The event featured a live demonstration of the system generating real-time patient consultation records, with plans to gradually roll it out across the entire MacKay healthcare network. |
| 2025-08-12 |
Exclusive Interview with Brain Navi: Secures U.S. 510(k) Clearance, Countdown to IPO Begins
|
Following the successful attainment of U.S. FDA 510(k) clearance for its brain surgery robot in May 2025, Taiwanese startup Brain Navi officially launches its countdown to IPO, aiming to list on the capital market in 2026. This will mark Brain Navi as Taiwan’s first company to enter the advanced surgical robot field with an independent brand. |
| 2025-08-12 |
Orient Europharma Group’s Subsidiary Orient Pharma Set to List on OTC, Plans to Launch New Alzheimer’s Drug
|
Orient Europharma Group’s promising subsidiary Orient Pharma is scheduled to be listed on the Taipei OTC market in late August, with a tentative underwriting price of NT$28.04. Orient Pharma held a pre-OTC performance briefing on July 29. General Manager Chun-Tung Huang stated on July 28 that Orient Pharma focuses on three major technology platforms and is actively investing in core areas such as cardiovascular and central nervous system diseases. The company currently has three marketed drugs and plans to launch four new products, including an anti-Alzheimer’s drug, over the next four years starting this year. |
| 2025-08-12 |
HCMED INNOVATIONS Reaches Breakthrough Milestone with FDA Approval for Innovative Breath-Activated Nebulizer
|
HCMED INNOVATIONS, specializing in inhalation drug-device combination CDMO products, announced that its breath-activated nebulizer AdheResp has recently received U.S. FDA 510(k) clearance. AdheResp is the world’s first FDA-cleared breath-activated nebulizer with built-in connectivity, and currently the only advanced nebulizer device with mass production capacity to support pharmaceutical clients’ clinical trials. |
| 2025-08-12 |
Tanvex BioPharma’s Biosimilar Drug Enters U.S. Market
|
Tanvex BioPharma-KY announced yesterday (25th) that since forming a strategic alliance with the Bora Group in January this year, it will now operate under the CDMO business brand “Bora Biologics” starting this week. Tanvex Chairman Bobby Sheng stated that the company’s first biosimilar drug, NYPOZ (reference original drug: Neupogen, a leukocyte growth factor), is set to officially launch in the U.S. market in the second half of this year. Additionally, the newly added 2,000-liter production line at the San Diego facility is scheduled to begin operations in the first quarter of next year. |
| 2025-08-12 |
Elixiron Immunotherapeutics’ New Drug EI-1071 Gains International Recognition
|
Refusing to let foreign pharmaceutical companies take the lead, Elixiron Immunotherapeutics is developing Enrupatinib (code-named EI-1071), a microglia-modulating drug that targets brain immune regulation, primarily for treating Alzheimer’s disease. This novel drug has been recognized by the Global Neurodegeneration Proteomics Consortium, founded by Bill Gates, and has currently advanced into Phase II clinical trials. |
